Upload map_terms.txt
Browse files- map_terms.txt +206 -0
map_terms.txt
ADDED
@@ -0,0 +1,206 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
</=,<=
|
2 |
+
>/=,>=
|
3 |
+
≤,<=
|
4 |
+
≥,>=
|
5 |
+
2nd generation,2nd-generation
|
6 |
+
5etc times/day,5x/day
|
7 |
+
Absorption t1/2,t1/2\a
|
8 |
+
Adverse drug reaction,ADR
|
9 |
+
Anti-proliferative ,Antiproliferative
|
10 |
+
Anti-rejection ,Antirejection
|
11 |
+
Area under curve,AUC
|
12 |
+
Average concentration,Cavg
|
13 |
+
Body-weight,Body weight
|
14 |
+
Broad spectrum,Broad-spectrum
|
15 |
+
Centi,c
|
16 |
+
Clearance,Cl
|
17 |
+
Compared to,cf
|
18 |
+
Complete response,CR
|
19 |
+
Composition-of-matter,Composition of matter
|
20 |
+
Day,day
|
21 |
+
Days,days
|
22 |
+
Deci,d
|
23 |
+
Decilitre,10ml
|
24 |
+
Dose-limiting toxicities,DLTs
|
25 |
+
Dose-limiting toxicity,DLT
|
26 |
+
double blind,double-blind
|
27 |
+
double masked,double-masked
|
28 |
+
Drug concentration producing 50% maximum response,EC50
|
29 |
+
Drug concentration that reduces response to another drug by 50%,IC50
|
30 |
+
early stage,early-stage
|
31 |
+
Effective dose in 50% patients,ED50
|
32 |
+
Elimination t1/2,t1/2\b
|
33 |
+
Every 10 days,q 10 days
|
34 |
+
Every 3 weeks,q 3wk
|
35 |
+
Extended Access,extended-access
|
36 |
+
Fast track,Fast-track
|
37 |
+
Fat rich,Fat-rich
|
38 |
+
For 3 weeks,x3wk
|
39 |
+
For 5 days,x5 days
|
40 |
+
Forced Expiratory Volume in 1 sec,FEV1
|
41 |
+
Four times a day,qid
|
42 |
+
Graft versus host,Graft-versus-host
|
43 |
+
Gram,g
|
44 |
+
Half-life,t1/2
|
45 |
+
Hour,hr
|
46 |
+
Hours,hr
|
47 |
+
International units,IU
|
48 |
+
Intramuscular,im
|
49 |
+
Intravenous,iv
|
50 |
+
Kaplan–Meier curves,KM curves
|
51 |
+
Kilo,k
|
52 |
+
Kilogram,kg
|
53 |
+
Litre/dm3,l
|
54 |
+
Maximum tolerated dose,MTD
|
55 |
+
Micro,\u
|
56 |
+
Microgram,\ug
|
57 |
+
Milli,m
|
58 |
+
Milligram,mg
|
59 |
+
Millilitre/cm3,ml
|
60 |
+
Minute,min
|
61 |
+
Minutes,min
|
62 |
+
Moderate to severe,Moderate-to-severe
|
63 |
+
Molar (NB,Mlar is the same as moles/litre or moles/dm3),M
|
64 |
+
Mole,mol
|
65 |
+
Month,mth
|
66 |
+
Months,mth
|
67 |
+
Nano,n
|
68 |
+
Nanogram,ng
|
69 |
+
Netherlands,The Netherlands
|
70 |
+
Non Randomized,non-randomized
|
71 |
+
Once daily,once-daily
|
72 |
+
Once weekly,1x/wk
|
73 |
+
Open label,open-label
|
74 |
+
Oral,po
|
75 |
+
Orally,po
|
76 |
+
Overall survival,OS
|
77 |
+
Parallel Assignment,parallel-assignment
|
78 |
+
Peak plasma conc.,Cmax
|
79 |
+
per day,/day
|
80 |
+
Pico,p
|
81 |
+
Picogram,pg
|
82 |
+
Placebo-controlled,placebo-controlled
|
83 |
+
Progression-free survival,PFS
|
84 |
+
Proof of concept,proof-of-concept
|
85 |
+
pts,patients
|
86 |
+
Quarter,qtr
|
87 |
+
Randomized,randomized
|
88 |
+
Second half of 2017,2nd half of 2017
|
89 |
+
Second,s
|
90 |
+
Seconds,s
|
91 |
+
Side effects,side-effects
|
92 |
+
Single Group,single-group
|
93 |
+
ß,beta
|
94 |
+
Stable disease,SD
|
95 |
+
Subcutaneous,sc
|
96 |
+
TEAEs,treatment-emergent adverse events
|
97 |
+
Three times a day,tid
|
98 |
+
Three times a week,3x/wk
|
99 |
+
Time to disease,Time-to-disease
|
100 |
+
Time to disease progression,Time-to-disease progression
|
101 |
+
Time to from admin. to Cmax,Tmax
|
102 |
+
Twice daily,bid
|
103 |
+
Twice per week,2x/wk
|
104 |
+
United Kingdom,The UK
|
105 |
+
United States,The US
|
106 |
+
Units,U
|
107 |
+
Versus,vs
|
108 |
+
Volume of distribution,Vd
|
109 |
+
Week,wk
|
110 |
+
Weeks,wk
|
111 |
+
Well-tolerated,Well tolerated
|
112 |
+
Year,yr
|
113 |
+
Years,yr
|
114 |
+
α,alpha
|
115 |
+
γ,gamma
|
116 |
+
δ,delta
|
117 |
+
σ,sigma
|
118 |
+
participants,subjects
|
119 |
+
The purpose of this study is,
|
120 |
+
The purpose of this study was,
|
121 |
+
The purpose of the study is,
|
122 |
+
The main aim of the study is,
|
123 |
+
The objective of the trial is,
|
124 |
+
The objective of the study is,
|
125 |
+
to find out,to evaluate
|
126 |
+
to demonstrate,to demonstrate
|
127 |
+
to see,to assess
|
128 |
+
to compare,to compare
|
129 |
+
to evaluate,to evaluate
|
130 |
+
to determine,to determine
|
131 |
+
to investigate,to investigate
|
132 |
+
study of, to evaluate
|
133 |
+
phase 1,Phase I
|
134 |
+
phase 2,Phase II
|
135 |
+
phase 3,Phase III
|
136 |
+
phase 1/2,Phase I/II
|
137 |
+
phase 2/3,Phase II/III
|
138 |
+
phase i,Phase I
|
139 |
+
phase ii,Phase II
|
140 |
+
phase iii,Phase III
|
141 |
+
one,1
|
142 |
+
two,2
|
143 |
+
three,3
|
144 |
+
four,4
|
145 |
+
five,5
|
146 |
+
six,6
|
147 |
+
seven,7
|
148 |
+
eight,8
|
149 |
+
nine,9
|
150 |
+
eleven,11
|
151 |
+
|,/
|
152 |
+
Placebo comparator,Placebo-controlled
|
153 |
+
Placebo controlled,Placebo-controlled
|
154 |
+
placebo control,Placebo-controlled
|
155 |
+
active comparator,active-controlled
|
156 |
+
open label,open-label
|
157 |
+
4-week,4 wk
|
158 |
+
3-Week,3 wk
|
159 |
+
British Approved Name,BAN
|
160 |
+
International Nonproprietary Name,INN
|
161 |
+
US Approved Name,USAN
|
162 |
+
Acute myelogenous leukaemia,AML
|
163 |
+
Acquired immune deficiency syndrome,AIDS
|
164 |
+
Blood pressure,BP
|
165 |
+
Chronic myelogenous leukaemia,CML
|
166 |
+
Chronic Obstructive Pulmonary Disease,COPD
|
167 |
+
Complete response,CR
|
168 |
+
Deep vein thrombosis,DVT
|
169 |
+
Forced Expiratory Volume in 1 sec,FEV1
|
170 |
+
Graft Versus Host disease,GvHD
|
171 |
+
Heart rate,HR
|
172 |
+
Hepatitis B/C virus,HBV/HCV
|
173 |
+
Herpes simplex virus,HSV
|
174 |
+
Highly active antiretroviral therapy,HAART
|
175 |
+
Human immunodeficiency virus,HIV
|
176 |
+
Inflammatory bowel disease,IBD
|
177 |
+
Irritable bowel syndrome,IBS
|
178 |
+
Multiple sclerosis,MS
|
179 |
+
Myocardial infarction,MI
|
180 |
+
Non-steroidal anti-inflammatory drug,NSAID
|
181 |
+
Osteoarthritis,OA
|
182 |
+
Partial response,PR
|
183 |
+
Rheumatoid arthritis,RA
|
184 |
+
Severe combined immunodeficiency,SCID
|
185 |
+
Simian immunodeficiency virus,SIV
|
186 |
+
Stable disease,SD
|
187 |
+
Systemic lupus erythramatosus,SLE
|
188 |
+
Biological Licence Application,BLA
|
189 |
+
Co-operative research and development agreement,CRADA
|
190 |
+
European Medicine Evaluation Agency,EMEA
|
191 |
+
European Union's Committee for Proprietary Medicinal Products,CPMP
|
192 |
+
Food and Drug Administration,FDA
|
193 |
+
Investigational New Drug,IND
|
194 |
+
Intellectual Property,IP
|
195 |
+
Marketing Authorization Approval,MAA
|
196 |
+
Medicine Control Agency,MCA
|
197 |
+
New Drug Application,NDA
|
198 |
+
Prescription Drug User Fee Act,PDUFA
|
199 |
+
tumor,tumour
|
200 |
+
tumors,tumours
|
201 |
+
leukemia,leukaemia
|
202 |
+
hematological,haematological
|
203 |
+
alzheimer's disease,Alzheimer's disease
|
204 |
+
egfr,EGFR
|
205 |
+
EGFR,EGFR
|
206 |
+
gilead,GILEAD
|